MAUDE adverse event: Acclaro Corporation - UltraClear

Reported to the FDA Sep 30, 2026 (event Aug 12, 2026). The FDA publishes these reports weeks after receipt. On (b)(6) 2026 the patient received UltraClear treatment. According to the patient impact form completed by the clinic, the treating physician immediately noticed that there was a